Consequently, NRs have emerged as promising molecular targets for MASLD treatment, and a few new NR-targeted drugs were approved recently, including thyroid hormone receptor-β (THR-β) agonist resmetirom, the dual peroxisome proliferator-activated receptor (PPAR)-α/γ agonist saroglitazar. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.